#1 Clinical Trials Search in Europe

Poa Pratensis

This article examines recent clinical trials investigating the use of Poa pratensis (Kentucky bluegrass) pollen extract in allergy immunotherapy. Poa pratensis is commonly included in grass pollen mixture vaccines being studied for treating allergic rhinitis, rhinoconjunctivitis, and mild asthma caused by grass pollen allergies. The trials aim to evaluate the efficacy and safety of these immunotherapy treatments in reducing allergy symptoms and medication use during pollen seasons.

Table of Contents

What is Poa Pratensis?

Poa pratensis, also known as Kentucky bluegrass, is a type of grass pollen that is commonly used in allergen extracts for the diagnosis and treatment of grass pollen allergies. It is often included in mixtures with other grass pollens to create comprehensive allergy treatments.[1]

Medical Uses

Poa pratensis is primarily used in the treatment of allergic conditions, including:

  • Allergic rhinitis (hay fever): Inflammation of the nasal passages caused by allergens
  • Allergic rhinoconjunctivitis: A combination of nasal and eye symptoms caused by allergens
  • Allergic asthma: Asthma triggered by allergens

These conditions can range from moderate to severe and may be intermittent (occurring only during certain seasons) or persistent (occurring year-round).[2]

How It Works

Poa pratensis and other grass pollen extracts are used in a treatment called allergen-specific immunotherapy. This therapy works by gradually exposing the patient to small amounts of the allergen, helping the immune system become less sensitive over time. This can lead to reduced allergic symptoms when exposed to grass pollen in the environment.[3]

Administration

Poa pratensis is typically administered as part of a mixture of grass pollen extracts. It can be given in two main ways:

  1. Subcutaneous immunotherapy (SCIT): Injections given under the skin, usually in the upper arm
  2. Sublingual immunotherapy (SLIT): Drops or tablets placed under the tongue

The treatment often follows a schedule that starts with a build-up phase of increasing doses, followed by a maintenance phase with regular doses over an extended period, typically several months to years.[4]

Effectiveness

Clinical trials have shown that immunotherapy containing Poa pratensis and other grass pollens can be effective in reducing allergy symptoms and the need for medication. Effectiveness is often measured using scales such as:

  • Total Combined Rhinitis Score (TCRS): A measure of nasal symptoms and medication use
  • Total Nasal Symptom Score (TNSS): A measure of nasal symptoms alone
  • Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ): A measure of how allergies impact daily life

Studies have shown improvements in these measures for many patients receiving grass pollen immunotherapy.[1]

Side Effects and Safety

While generally considered safe when administered under medical supervision, immunotherapy with Poa pratensis and other grass pollens can cause side effects, including:

  • Local reactions at the injection site (for SCIT)
  • Itching or swelling in the mouth (for SLIT)
  • In rare cases, more severe allergic reactions

Patients with certain conditions, such as severe or uncontrolled asthma, may not be suitable candidates for this treatment. Always discuss potential risks and benefits with your healthcare provider.[2]

Ongoing Research

Research on grass pollen immunotherapy, including treatments containing Poa pratensis, is ongoing. Current studies are investigating:

  • Optimal dosing strategies
  • Long-term effectiveness
  • Combination therapies with other allergens
  • Effects on asthma control
  • Immunological changes in response to treatment

These studies aim to further improve the effectiveness and safety of grass pollen immunotherapy for patients with allergic conditions.[4]

Aspect Details
Study Focus Immunotherapy for grass pollen allergies, including Poa pratensis
Target Conditions Allergic rhinitis, rhinoconjunctivitis, mild-moderate asthma
Treatment Forms Subcutaneous injections, polymerized allergen extracts
Primary Outcomes Reduction in allergy symptoms and medication use during pollen seasons
Secondary Outcomes Quality of life improvements, immunological changes, safety assessments
Study Designs Randomized, double-blind, placebo-controlled trials
Patient Age Range Typically 12-65 years old
Treatment Duration Generally up to 12 months
Key Inclusion Criteria History of grass pollen allergy, positive skin prick tests, elevated specific IgE
Safety Considerations Monitoring for local and systemic reactions, exclusion of severe asthmatics

FAQ

  • What is Poa pratensis and why is it being studied in allergy trials? Poa pratensis, also known as Kentucky bluegrass, is a type of grass pollen commonly included in allergy immunotherapy vaccines. It's being studied because it's a major cause of grass pollen allergies, which can trigger symptoms like allergic rhinitis and asthma in sensitive individuals.
  • What are the main goals of these clinical trials? The main goals are to assess the effectiveness and safety of immunotherapy vaccines containing Poa pratensis and other grass pollens in reducing allergy symptoms, decreasing medication use, and improving quality of life for patients with grass pollen allergies.
  • How is the effectiveness of the treatments measured? Effectiveness is measured through various means, including symptom scores, medication use scores, quality of life questionnaires, immunological tests (like IgE and IgG4 levels), and provocation tests to assess changes in allergen tolerance.
  • Who can participate in these clinical trials? Participants are typically adults and adolescents (ages vary by study, but generally 12-65 years old) with a documented history of grass pollen allergies, positive skin prick tests and/or specific IgE tests to grass pollens, and moderate to severe allergy symptoms during grass pollen seasons.
  • Are there any risks associated with participating in these trials? While immunotherapy is generally considered safe, there can be risks such as local reactions at the injection site or, rarely, more severe allergic reactions. The trials closely monitor participants for any adverse events and have safety protocols in place. People with certain health conditions or severe asthma may be excluded from participating for safety reasons.

Ongoing Clinical Trials on Poa Pratensis

  • Study on the Effectiveness of PURETHAL Mites for Adults with Moderate to Severe Allergic Rhinitis or Rhinoconjunctivitis Due to House Dust Mite Allergy

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Bulgaria Germany Latvia Lithuania Poland

Glossary

  • Allergic rhinitis: An allergic inflammation of the nasal passages, causing symptoms like sneezing, runny nose, and nasal congestion in response to allergens like pollen.
  • Rhinoconjunctivitis: A combination of rhinitis (nasal symptoms) and conjunctivitis (eye symptoms) caused by allergies, resulting in symptoms affecting both the nose and eyes.
  • Immunotherapy: A treatment approach that aims to modify the immune system's response to allergens, typically by administering gradually increasing doses of an allergen to build tolerance.
  • Poa pratensis: The scientific name for Kentucky bluegrass, a common type of grass whose pollen is a significant cause of grass allergies.
  • Skin prick test: A diagnostic test for allergies where small amounts of suspected allergens are placed on the skin, which is then pricked, to observe any allergic reactions.
  • Specific IgE: Immunoglobulin E antibodies that are specific to a particular allergen, measured in blood tests to diagnose allergies.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function used to assess and monitor asthma.
  • ARIA classification: Allergic Rhinitis and its Impact on Asthma, a system for classifying the severity and duration of allergic rhinitis symptoms.
  • Polymerized extract: An allergen extract that has been chemically modified to reduce allergenicity while maintaining immunogenicity, used in some immunotherapy formulations.
  • Conjunctival Provocation Test (CPT): A diagnostic test where allergen is applied to the eye to assess the allergic response, used to evaluate the effectiveness of immunotherapy.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-purethal-mites-for-adults-with-moderate-to-severe-allergic-rhinitis-or-rhinoconjunctivitis-due-to-house-dust-mite-allergy/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-a-grass-and-juniperus-oxycedrus-allergy-vaccine-for-patients-with-allergic-rhinitis-or-rhinoconjunctivitis-with-or-without-mild-asthma/
  3. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-beltavac-with-grass-pollen-extract-for-patients-with-allergic-rhinoconjunctivitis-and-possible-asthma/
  4. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-a-grass-and-olive-pollen-allergy-vaccine-for-patients-with-allergic-rhinitis-or-asthma/